Highlights Tarsus Pharmaceuticals, Inc.

Equities

TARS

US87650L1035

Real-time Estimate Cboe BZX Other stock markets 11:21:11 2024-05-21 am EDT			5-day change	1st Jan Change
38.82 ^USD	+0.23%		+1.95%	+91.26%

May. 15	Transcript : Tarsus Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 01:55 PM
May. 09	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q1 Revenue $27.6M, vs. Street Est of $17.9M	May. 08	MT
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals	Apr. 24	AN
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc	Mar. 27	CI
Tarsus Pharmaceuticals' Q4 Net Loss Widens, Revenue Increases	Feb. 27	MT
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q4 Revenue $13.1M, vs. Street Est of $5.9M	Feb. 27	MT
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Tarsus Announces Positive Topline Results from Carpo, A Phase 2A Proof-Of-Concept ?Tick-Kill? Trial Evaluating Tp-05 for the Prevention of Lyme Disease	Feb. 22	CI
Tarsus Pharmaceuticals, Inc. Announces Positive Topline Results from the Ersa Phase 2A Clinical Trial Evaluating Tp-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites	Dec. 11	CI
Tarsus Pharmaceuticals Rose 5% in After-Hours Activity Thursday After Q3 Sales Beat Market Expectations	Nov. 10	MT
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Reports Q3 Revenue $1.9M, vs. Street Est of $0.4M	Nov. 09	MT
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Tarsus Pharmaceuticals, Inc. Announces Availability of XDEMVY? (Lotilaner Ophthalmic Solution) 0.25%	23-08-24	CI
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
LianBio, Tarsus Pharmaceuticals Get US FDA Approval For Xdemvy in Treating Eye Disease Demodex Blepharitis	23-07-26	MT
FDA Approves Tarsus Pharmaceuticals, Inc.'s XDEMVY(TM) (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex blepharitis	23-07-25	CI
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer	23-04-24	GL
TARSUS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Tarsus Pharmaceuticals, Inc.

Equities

TARS

US87650L1035

Highlights

Filters